STING1 and colorectal carcinoma: Collectively, these results highlight that the novel topoisomerase I inhibitor TLC388 promotes antitumor immunity via STING, offering novel therapeutic avenues to enhance treatment response in ICI-unresponsive tumors, such as MSS-CRC.